Science
Lekha Mikkilineni
Lekha Mikkilineni/conquer.org

Lekha Mikkilineni: Studying Stem Cell Mobilization in the CD38-mAb Era

Lekha Mikkilineni, Assistant Professor in the BMT Division at Stanford University School of Medicine, shared a post on X about a paper published on Transplantation and Cellular Therapy:

“We studied stem cell mobilization in the CD38-mAb era.

In NDMM patients undergoing ASCT, CD38-mAb induction led to:

  • Decreased yields (−9.4%)
  • Increased plerixafor and apheresis
  • +$23K mobilization costs Longer washout improved yields.”

Title: The Impact of Anti-CD38 Monoclonal Antibody Therapy on Stem-Cell Mobilization Yields in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Referred from Community and Academic Oncology Practices: Single Center, Real World Data 2021-2024

Authors: Dilek Uzun, Jeddeo Michael Paul, Alexandria Jensen, John Tamaresis, Walter Domingo, Sally Arai, Felipe Araya Ventura, Jennifer Rocha, Leslie Bennett, Amelia Jones, Sushma Bharadwaj, Laura Johnston, Robert Lowsky, Andrew Rezvani, Parveen Shiraz, Judith Shizuru, Wen-Kai Weng, Hitomi Hosoya, Surbhi Sidana, David Miklos, Lori Muffly, Lekha Mikkilineni

Read the full article.

Lekha Mikkilineni

More posts featuring Lekha Mikkilineni on OncoDaily.

Alexandria Jensen Amelia Jones Andrew Rezvani cancer CD38-mAb David Miklos Dilek Uzun Felipe Araya Ventura Hitomi Hosoya Jeddeo Michael Paul Jennifer Rocha John Tamaresis Judith Shizuru Laura Johnston Lekha Mikkilineni Leslie Bennett Lori Muffly OncoDaily Oncology Parveen Shiraz Robert Lowsky Sally Arai stem cell mobilization Surbhi Sidana Sushma Bharadwaj transplantation and cellular therapy Walter Domingo Wen-Kai Weng